HexemBio

Advanced stem cell rejuvenation therapy

Seed
New York City, USA
Founded 2023
Website

About

HexemBio, founded to combat aging and disease through blood stem cell restoration, develops scalable stem cell rejuvenation therapies addressing the decline of blood stem cells linked to aging and cancer. The NYC and Berkeley-based biotech startup leverages cutting-edge science to create reproducible treatments that restore youthful blood function, funded by a $10.4M seed round led by Draper Associates. Their business model focuses on novel therapeutic development targeting foundational aging mechanisms for long-term healthspan extension.

Products

  • Rejuvenated Stem Cell Therapy — Restores aged hematopoietic stem cells to improve white blood cells, red blood cells, and platelets for better immunity and faster recovery.
    Customer sectors: hematologists, blood cancer researchers, regenerative medicine
  • The Yolk Sac Method — Rejuvenates hematopoietic stem cells by accessing their early developmental state to restore youthful function and improve health.
    Customer sectors: stem cell researchers, regenerative medicine, biotech developers
  • Synthetic Young Niche for HSC Rejuvenation — Provides an engineered synthetic niche that rejuvenates hematopoietic stem cells to enhance their function and scalability.
    Customer sectors: biotech firms, stem cell therapy developers, regenerative medicine

Company Details

Sector Deep Tech
Category Biotech & Therapeutics
Stage Seed
Total Funding $10.4M
Employees 11-50
Last Funded April 6, 2026
Last Round $10.4M

Market research & competitive positioning

Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for HexemBio — available to members.

Create a free account Sign in